Lotus Reports July 2026 Revenue of NT$2,492 Million

Taipei, Taiwan, 10 August 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for July 2026 of NT$2,492 million, representing an increase of 4% YoY, mainly driven by strong growth in the B2B business and solid performance across key Asian markets, particularly Korea and Thailand. Lotus' year-to-date (YTD) July 2026 revenue reached NT$19,945 million, an increase of 68% compared to the same period last year, continued to be supported by Alvogen as well as strong momentum in the B2B business.

For the first seven months ending July 2026, revenue from US grew 133% YoY to NT$11,902 million for the period, representing c. 60% of the total consolidated revenue, driven by the consolidation of Alvogen. Lotus’ Asia business remained stable with revenue of NT$6,354 million, representing c.32% of the Group’s total consolidated revenue. Lotus’ B2B business grew 233% YoY to NT$1,688 million, contributing c.9% of total consolidated revenue, supported by key product launches* such as Nintedanib in Europe and North America as well as Enzalutamide in Brazil, Canada and South Korea.

*For B2B markets, “launch” refers to the initial product shipment to a partner; in-market launch timing is subject to local commercial arrangements.

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness